Important pharmacy news and late-breaking industry information updated daily.

U.S. health spending is expected to grow at an average annual rate of 5.5% in the next decade, CMS's Office of the Actuary reported Wednesday. National health expenditures are expected to reach nearly $6 trillion by 2027, the report said.

FDA is cautioning consumers about establishments that are offering infusions of plasma from young donors that claim to treat the effects of a number of conditions, ranging from normal aging and memory loss to dementia, multiple sclerosis, and post-traumatic stress disorder.

Thousands of drugs are recalled each year after reaching pharmacy shelves and ultimately the homes of unsuspecting people across the country, according to the findings of a recent Kaiser Health News (KHN) investigation. The ever-expanding recalls of medications containing losartan and valsartan have garnered significant attention in the media. However, these recalls may be just one example of a problem that is more widespread than previously thought.

The flu season strengthened in February, but according to the latest statistics from CDC, this has been a low-severity flu season overall. As outlined in the February 15 issue of CDC’s Morbidity and Mortality Weekly Report, outpatient visits for flu-like illness are low, as are hospitalization rates. Compared with recent flu seasons, fewer deaths are being attributed to pneumonia and influenza, as well.

A Washington state House committee on February 15 passed a bill to ban the personal or philosophical exemption for the vaccine against measles, mumps, and rubella (MMR) for school-age children amid an outbreak of the highly infectious virus.

Interim estimates from CDC suggest that this year's influenza vaccine is providing about 47% protection against all influenza infections.

FDA announced in February the launch of a pilot project program to test innovative ways for drug supply chain members to overcome barriers in the development of the enhanced electronic, interoperable “track-and-trace” system. The pilot project program seeks applications from groups of trading partners, including pharmacies, to take an active role in testing advance systems that are expected to inform how final track-and-trace systems will work as Drug Supply Chain Security Act (DSCSA) implementation progresses.

FDA Commissioner Scott Gottlieb, MD, discussed on Wednesday steps the agency is taking to support efficiency in drug development and FDA's oversight of drug quality.

FDA Commissioner Scott Gottlieb discusses the agency's efforts to stop the spread of illicit opioids and further secure all aspects of the supply chain for legitimate medications, including opioids. On Tuesday, the agency announced it has issued its first warning letter under the Drug Supply Chain Security Act (DSCSA) to McKesson Corp.

According to a modified Risk Evaluation and Mitigation Strategy (REMS) program for clozapine, starting February 28, 2019, pharmacists are no longer allowed to enroll patients in the Clozapine REMS Program, and pharmacies must also be certified to dispense clozapine.